Pantos Constantinos, Mourouzis Iordanis, Xinaris Christodoulos, Papadopoulou-Daifoti Zoi, Cokkinos Dennis
Department of Pharmacology, University of Athens, 75 Mikras Asias Ave., 11527 Goudi, Athens, Greece.
Pharmacol Ther. 2008 May;118(2):277-94. doi: 10.1016/j.pharmthera.2008.02.011. Epub 2008 Mar 20.
Recent research has revealed novel actions of thyroid hormone (TH) on the heart which may be of important physiological and therapeutic relevance. TH, apart from its "classical" actions on cardiac contractility and heart rhythm, appears to regulate various intracellular signaling pathways related to stress responses and cardiac remodelling. Accumulating experimental evidence suggests that changes in TH may constitute an important component in the pathophysiology of heart failure. In fact, TH seems to be a "switch" for the fetal cardiac phenotype. Changes in the TH-thyroid hormone receptor axis are also evident in patients with heart failure and associated with impaired cardiac function and increased mortality. More importantly, experimental and clinical studies demonstrate that TH can limit ischaemic injury, attenuate cardiac remodeling and improve cardiac hemodynamics. TH analogs have already been developed and may allow exploitation of the TH-thyroid hormone receptor in clinical practice. At present, the therapeutic potential and efficacy of TH in the treatment of cardiac diseases await evaluation in large clinical trials.
最近的研究揭示了甲状腺激素（TH）对心脏的新作用，这可能具有重要的生理和治疗意义。TH除了对心脏收缩力和心律有“经典”作用外，似乎还调节与应激反应和心脏重塑相关的各种细胞内信号通路。越来越多的实验证据表明，TH的变化可能是心力衰竭病理生理学的重要组成部分。事实上，TH似乎是胎儿心脏表型的“开关”。TH-甲状腺激素受体轴的变化在心力衰竭患者中也很明显，并且与心脏功能受损和死亡率增加有关。更重要的是，实验和临床研究表明，TH可以限制缺血性损伤，减轻心脏重塑并改善心脏血流动力学。TH类似物已经开发出来，可能会在临床实践中利用TH-甲状腺激素受体。目前，TH在治疗心脏病方面的治疗潜力和疗效有待大型临床试验评估。
